Juvenile Psoriatic Arthritis study: Adalimumab vs Risankizumab
Official title A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
ClinicalTrials.gov ID: NCT06100744
What this study is testing
What is Adalimumab?
Adalimumab is an investigational medicine, given as an injection under the skin, being studied as a potential treatment for juvenile psoriatic arthritis.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to learn how safe risankizumab is and whether it improves disease activity compared with adalimumab.
- Who it's for
- Children under 16 years old who have been diagnosed with juvenile psoriatic arthritis.
- What's involved
- Participants will receive weight‑based subcutaneous injections of either risankizumab or adalimumab, attend regular clinic visits, and undergo medical exams, blood tests, side‑effect checks, and questionnaires.
- Time commitment
- The trial lasts at least 24 weeks, with responders continuing the same treatment for up to another 100 weeks, plus a safety follow‑up of 70‑140 days after the last dose.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 5 to 17
You may be able to join if
- Diagnosis of juvenile psoriatic arthritis (jPsA) according to International League of Associations for Rheumatology criteria for at least 3 months...
- Active Disease in \>= 3 joints at screening and at Baseline (swelling not due to deformity, or limitation of motion with pain, tenderness, or both)...
- Have had an inadequate response (lack of how well it works after minimum 2-month duration of therapy at maximally tolerated dose), or intolerance to...
You likely can't join if
- Have any other autoimmune disease, rheumatic disease (including systemic Juvenile idiopathic arthritis [JIA], rheumatoid factor-positive or...
- Prior inadequate response to treatments in the anti-TNF or IL-23 inhibitor classes.
The study team makes the final eligibility decision.
Where it is enrolling
- Little Rock, Arkansas, United States
- Washington D.C., District of Columbia, United States
- Hollywood, Florida, United States
- Miami, Florida, United States
- Indianapolis, Indiana, United States
- Minneapolis, Minnesota, United States
- New York, New York, United States
- Valhalla, New York, United States
- Chapel Hill, North Carolina, United States
- Cleveland, Ohio, United States
- Austin, Texas, United States
- Clayton, Victoria, Australia
- Calgary, Alberta, Canada
- Vancouver, British Columbia, Canada
- Toronto, Ontario, Canada
- Bordeaux, New Aquitaine, France
- Le Kremlin-Bicêtre, Paris, France
- Sankt Augustin, North Rhine-Westphalia, Germany
- Berlin, Germany
- Hamburg, Germany
+ 13 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 5 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Little Rock, Arkansas, United States; Washington D.C., District of Columbia, United States; Hollywood, Florida, United States; Miami, Florida, United States; Indianapolis, Indiana, United States; Minneapolis, Minnesota, United States and 27 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.